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background: Heart failure (HF) is the leading cause of 30-day all-cause readmission, the reduction of which is a goal of the Affordable Care Act. 
Prior studies (AHA 2013) suggest that beta-blockers and aldosterone antagonists may not lower 30-day all-cause readmission in HF and reduced 
EF (HFrEF). In the current analysis, we examined if ACE inhibitor or angiotensin receptor blocker (ACEI-ARB) use is associated with 30-day all-cause 
readmission.
methods: Of the 1384 Medicare beneficiaries with acute decompensated HF and EF<45%, discharged alive from 106 U.S. hospitals (1998-2001), 
with no prior ACEI-ARB use and no contraindications, 734 received pre-discharge prescriptions for these drugs. Using propensity scores for ACEI-ARB 
use, we assembled a matched cohort of 477 pairs of patients balanced on 32 baseline characteristics.
results: 30-day all-cause readmissions occurred in 18% and 24% of matched patients receiving and not receiving ACEI-ARBs, respectively (HR, 
0.74; 95% CI, 0.56-0.97; p=0.030; Figure). This association persisted during 12 months post-discharge (HR, 0.81; 95% CI, 0.69-0.95). The use of 
ACEI-ARB was also associated with lower 30-day HF readmission (HR, 0.52; 95% CI, 0.35-0.79) and 30-day all-cause mortality (HR, 0.56; 95% CI, 
0.33-0.98).
conclusions: Among hospitalized patients with HFrEF, a pre-discharge initiation of ACE inhibitor or ARB was associated with significantly lower 30-
day all-cause readmission, 30-day HF readmission and 30-day all-cause mortality.
